In-vitro and in-vivo anti-inflammatory effect of oxyresveratrol from Morus alba L.
The antioxidative effects of mulberroside A and oxyresveratrol obtained from Mori Cortex were examined. Mulberroside A and oxyresveratrol showed an inhibitory effect against FeSO4/H2O2-induced lipid peroxidation in rat microsomes and a scavenging effect on 1,1-diphenyl-2-picrylhydrazyl radical. The anti-inflammatory effects of mulberroside A and oxyresveratrol using the carrageenin-induced model of inflammation were investigated in rats. Mulberroside A and oxyresveratrol significantly reduced paw edema. To investigate the mechanism of the anti-inflammatory action of these compounds, we examined the effects of oxyresveratrol on lipopolysaccharide (LPS)-induced responses in murine macrophage cell line RAW 264.7. Exposure of LPS-stimulated cells to oxyresveratrol inhibited nitrite accumulation in the culture medium. Oxyresveratrol also inhibited the LPS-stimulated increase of inducible nitric oxide synthase (iNOS) expression in a concentration-dependent manner; however, it had little effect on iNOS enzyme activity, suggesting that the inhibitory activity of oxyresveratrol is mainly due to the inhibition of iNOS expression rather than iNOS enzyme activity. Oxyresveratrol significantly inhibited LPS-evoked nuclear translocation of NF-kappaB and cyclooxygenase-2 (COX-2) activity in RAW 264.7 cells. The results suggest that the anti-inflammatory properties of oxyresveratrol might be correlated with inhibition of the iNOS expression through down-regulation of NF-kappaB binding activity and significant inhibition of COX-2 activity.
Chung
Kyung-Ook
KO
College of Pharmacy, Pusan National University, Keumjeonggu, Pusan 609-735, Korea.
Kim
Bo-Young
BY
Lee
Myung-Hee
MH
Kim
Yeo-Ryun
YR
Chung
Hae-Young
HY
Park
Jong-Hee
JH
Moon
Jeon-Ok
JO
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use*; D002478:Cells, Cultured; D015232:Dinoprostone / Q000096:biosynthesis; D004187:Disaccharides / Q000627:therapeutic use*; D004487:Edema / Q000188:drug therapy*; D007249:Inflammation / Q000188:drug therapy*; D015227:Lipid Peroxidation / Q000187:drug effects*; D008297:Male; D008862:Microsomes, Liver / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D031625:Morus; D019001:Nitric Oxide Synthase / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use*; D028321:Plant Preparations / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013267:Stilbenes / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D004187:Disaccharides; D010936:Plant Extracts; D028321:Plant Preparations; D013267:Stilbenes; C420606:mulberroside A; C034912:puag-haad; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat; D015232:Dinoprostone